1 |
Hooper DC. Mode of action of fluoroquinolones. Drug 1999;58(Suppl 2):S6-10.
DOI
|
2 |
Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of quinolone antibacterial agents. Yakushigaku Zasshi 2003;38(2):161-79.
|
3 |
Owens RC, Jr., Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144-57.
DOI
|
4 |
Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug safety 1999;21(5):407-21.
DOI
|
5 |
Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002;65(3):455-64.
|
6 |
Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001;47(Suppl 3):S3-8, S44-8.
|
7 |
Moller PL, Sindet-Pedersen S, Petersen CT, et al. Onset of acetaminophen analgesia: comparison of oral and intravenous routes after third molar surgery. Br J Anaesth 2005;94(5):642-48.
DOI
|
8 |
Reimann W, Schneider F. Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine. Eur J Pharmacol 1998;349(2-3):199-203.
DOI
|
9 |
Gobbi M, Moia M, Pirona L, et al. p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J Neurochem 2002;82(6):1435-43.
DOI
|